ReviewFrontiers in molecular biosciences2026
The function of phosphoglycerate mutase 1 (PGAM1) and its role in diseases.
Review in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Phosphoglycerate mutase 1 (PGAM1) is a pivotal metabolic enzyme during the process of glycolysis, catalyzing the interconversion between 3-phosphoglycerate and 2-phosphoglycerate. PGAM1 is mainly involved in cellular energy metabolism and biosynthesis, it is generally upregulated in numerous human cancers and promotes cell proliferation, invasion, and drug resistance. It serves as a significant biomarker for tumor diagnosis and a potential therapeutic target. In this paper, the basic structure and functions of PGAM1 and its family members, metabolic, non-metabolic activity and the regulatory mechanisms of PGAM1 and its correlation with diseases, as well as the latest progress of PGAM1 inhibitors in tumor diagnosis and treatment are introduced, aiming to provide new ideas for the targeted therapy of related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.